Akeso Full Year 2022 Earnings: Misses Expectations

Akeso (HKG:9926) Full Year 2022 Results

Key Financial Results

• Revenue: CN¥837.7m (up 271% from FY 2021).
• Net loss: CN¥1.17b (loss widened by 8.7% from FY 2021).
• CN¥1.42 loss per share (further deteriorated from CN¥1.32 loss in FY 2021).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Akeso Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) also missed analyst estimates by 4.8%.

Looking ahead, revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 34% growth forecast for the Biotechs industry in Hong Kong.

Performance of the Hong Kong Biotechs industry.

The company's shares are up 17% from a week ago.

Risk Analysis

You should learn about the 1 warning sign we've spotted with Akeso.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.